Assistant Professor, Medicine, Vanderbilt University School of Medicine
Infectious Disease
Dr. Todd M. Hulgan, MD
|
|
Give Review
Todd Hulgan is an expert in the field of Infectious Disease. He went to University of Alabama School of Medicine. University of Alabama School of Medicine has a rank of 37 in research and a 17 in primary care Todd Hulgan is also a published doctor. He has 46 paper published. The most recent paper is: Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection. He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection.
- Epidermal nerve fiber density, oxidative stress, and mitochondrial haplogroups in HIV-infected Thais initiating therapy.
- Mitochondrial DNA Variation and Changes in Adiponectin and Endothelial Function in HIV-Infected Adults After Antiretroviral Therapy Initiation.
- Circulating interleukin-6, soluble CD14, and other inflammation biomarker levels differ between obese and non-obese HIV-infected adults on antiretroviral therapy.
- Active cocaine use is associated with lack of HIV-1 virologic suppression independent of nonadherence to antiretroviral therapy: Use of a rapid screening tool during r...
- HIV and Mitochondria: More than Just Drug Toxicity.
- Current drug use and lack of HIV virologic suppression: point-of-care urine drug screen versus self-report.
- Genetic Variation in Iron Metabolism Is Associated with Neuropathic Pain and Pain Severity in HIV-Infected Patients on Antiretroviral Therapy.
- Urinary Eicosanoid Metabolites in HIV-Infected Women with Central Obesity Switching to Raltegravir: An Analysis from the Women, Integrase, and Fat Accumulation Trial.
- The Other Genome: A Systematic Review of Studies of Mitochondrial DNA Haplogroups and Outcomes of HIV Infection and Antiretroviral Therapy.
- Mitochondrial genomics and CD4 T-cell count recovery after antiretroviral therapy initiation in AIDS clinical trials group study 384.
- Drug Use and Receipt of Highly Active Antiretroviral Therapy among HIV-Infected Persons in Two U.S. Clinic Cohorts.
- The relationship between injection and noninjection drug use and HIV disease progression.
- QSART for diagnosis of statin-associated polyneuropathy.
- Race, kidney disease progression, and mortality risk in HIV-infected persons.
- European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142.
- Estimating the optimal CD4 count for HIV-infected persons to start antiretroviral therapy.
- Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infecte...
- African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy.
- Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study.
- Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors.
- Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults.
- Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy.
- Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care.
- Sociodemographic factors predict early discontinuation of HIV non-nucleoside reverse transcriptase inhibitors and protease inhibitors.
- Cross-cohort heterogeneity encountered while validating a model for HIV disease progression among antiretroviral initiators.
- High-concentration capsaicin reduced pain in patients with HIV-associated polyneuropathy.
- Higher plasma myeloperoxidase levels are not associated with an increased risk for cardiovascular events in HIV-infected adults.
- Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy.
- Phosphodiesterase type-5 inhibitors and the reemerging HIV epidemic.
- Human genomic association studies: a primer for the infectious diseases specialist.
- Agreement of decision analyses and subsequent clinical studies in infectious diseases.
- Identification of a CCR5-expressing T cell subset that is resistant to R5-tropic HIV infection.
- Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral the...
- Toward a pharmacogenetic understanding of nucleotide and nucleoside analogue toxicity.
- Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy.
- Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group study.
- CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphoc...
- Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study.
- Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons.
- Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.
- Oxidant stress is increased during treatment of human immunodeficiency virus infection.
- Implications of T-cell P-glycoprotein activity during HIV-1 infection and its therapy.
- Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy.
- Increased susceptibility of the sickle cell membrane Ca2+ + Mg(2+)-ATPase to t-butylhydroperoxide: protective effects of ascorbate and desferal.
Schools
Univ Of Al Sch Of Med
Wake Forest University Bapt Mc
Vanderbilt University Mc
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
Education
-
Vanderbilt University -
Wake Forest University -
University of Alabama School of Medicine
Hospital
-
Vanderbilt Hospital and Clinics
Drug Facts
| NPI NUMBER | 1740377878 | |
| NPPES Provider LastName | HULGAN | |
| NPPES Provider FirstName | TODD | |
| NPPES Provider ZIPCode | 372320001 | |
| NPPES Provider State | TN | |
| Specialty Description | Infectious Disease | |
| Total Claim Count | 329.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 17.0 | |
| Percent Opioid Claims | 5.17 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1740377878 |
| Last Name Of The Provider | HULGAN |
| First Name Of The Provider | TODD |
| View All |
Similar Doctors
|
|
Dr. Patty Wright, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen P. Raffanti, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Julie Reznicek, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wendy J. Mangialardi, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Tracy J. Osborne, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William Schaffner II, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy R. Sterling, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lora Thomas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jayesh A. Patel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael J. Noto, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark A. Pilkinton, MD
This Doctor is OpenDoctor Recommended.
|